#3 Best: Kinetics Medical
Since 1999, Paul Abel has managed the Kinetics Medical Fund (MUTF:MEDRX), which focuses on pharma and biotech investments. These sectors were certainly red-hot in the latest quarter, and the fund was positioned nicely to capitalize on this.
Abel takes a long-term perspective on things, considering the time it can take to get drugs to approval. The fund is so long-term-focused, in fact, that MEDRX’s turnover ratio is listed as 0%.
Speaking of long-term, that’s also the time horizon of the fund’s past success. MEDRX has averaged nearly 9% annual returns since inception in 1999.